TESLA WATCH: Elon Musk Pay Deal In Focus Novo Nordisk (NVO) said it would pay up to $10 billion to acquire obesity-focused Metsera (MTSR), topping Pfizer's (PFE) recently hiked $8.1 billion proposal. The news sent Metsera stock flying more than 15% to 70. Meanwhile, Pfizer stock rose a fraction, while Novo shares gained 1.2%. Pfizer and Metsera have been locked in a heated battle over the last week to buy Metsera. Pfizer's first bid, in September, was for $4.9 billion. Last week, Novo Nordisk made an unsoli ...

Shares of Eli Lilly and Novo Nordisk rose on a report that the companies were preparing to announce new deals with the White House to lower prices for weight-loss drugs in exchange for coverage under Medicare https://t.co/YdXdExhnK1 ...

Core Viewpoint - Metsera's stock price surged over 15% to $70.42 amid intensified bidding from Pfizer and Novo Nordisk for the company, with Novo Nordisk's latest offer deemed more favorable by Metsera's board [1] Group 1: Acquisition Bids - Novo Nordisk raised its acquisition offer to a total value of $86.20 per share, comprising $62.20 in cash and up to $24 in contingent value rights, contingent on achieving commercialization or regulatory milestones [1] - Pfizer's updated bid stands at approximately $70 per share, totaling around $8.1 billion, which is significantly lower than Novo Nordisk's proposal and categorized as a "less favorable offer" [1] Group 2: Market Context - The acquisition battle centers on Metsera's core asset, a late-stage candidate for weight loss and metabolic diseases, seen as a potential "next-generation blockbuster" following Wegovy and Zepbound [2] - The global weight loss drug market is projected to exceed $100 billion by 2030, indicating rapid expansion and increasing competition among innovative pharmaceutical companies [2] - The competition reflects the pressures large pharmaceutical companies face from patent expirations and the need to replenish their product pipelines [2] Group 3: Future Developments - Market attention will remain on whether Pfizer will increase its bid within the next 48 hours and the ultimate direction of the transaction as determined by Metsera's board [3]

Core Viewpoint - Metsera's stock price surged over 15% to $70.42 amid intensified bidding from Pfizer and Novo Nordisk for the company, with Novo Nordisk's latest offer deemed more favorable by Metsera's board [1] Group 1: Acquisition Bids - Novo Nordisk raised its acquisition proposal to a total value of $86.20 per share, comprising $62.20 in cash and up to $24 in contingent value rights, contingent on achieving specific commercialization or regulatory milestones [1] - Pfizer's updated bid is approximately $70 per share, totaling around $8.1 billion, which is significantly lower than Novo Nordisk's offer and categorized as a "less favorable bid" [1] Group 2: Market Context - The bidding war centers on Metsera's core asset, a late-stage candidate for weight loss and metabolic diseases, seen as a potential "next-generation blockbuster" following Wegovy and Zepbound [1] - The global obesity treatment market is rapidly expanding, with Morgan Stanley estimating that the market for weight loss drugs could exceed $100 billion by 2030 [1] Group 3: Industry Dynamics - The competition between Pfizer and Novo Nordisk highlights the pressures large pharmaceutical companies face from patent expirations and the need to replenish their product pipelines [2] - There is a possibility that Pfizer may withdraw from the bidding if it fails to submit a higher offer within the stipulated timeframe [2] Group 4: Market Monitoring - The market will closely watch whether Pfizer increases its bid within the next 48 hours and the final decision of Metsera's board regarding the acquisition [3]

Core Insights - Eli Lilly and Novo Nordisk are set to announce new drug pricing agreements with the White House, specifically for their popular weight loss medications [1] - These agreements are expected to include provisions for coverage of their products under Medicare [1] Company Summary - Eli Lilly is preparing to negotiate drug pricing deals that will likely enhance its market position in the weight loss drug sector [1] - Novo Nordisk is also involved in similar negotiations, indicating a competitive landscape in the pharmaceutical industry focused on weight management solutions [1] Industry Summary - The pharmaceutical industry is witnessing significant developments as major companies like Eli Lilly and Novo Nordisk engage with the government to secure favorable pricing and coverage terms [1] - The outcome of these negotiations could impact drug accessibility and pricing strategies across the industry, particularly for weight loss medications [1]

每经AI快讯，11月4日，诺和诺德欧股短线跳水，跌幅扩大至超过2%。 （文章来源：每日经济新闻） ...

Core Viewpoint - Novo Nordisk's new bid for Metsera is considered superior to Pfizer's revised offer, intensifying competition between the two pharmaceutical companies in the obesity biotech sector [1][2]. Group 1: Bid Details - Novo Nordisk's proposal values Metsera at up to $86.20 per share, totaling approximately $10 billion, which represents a 159% premium over Metsera's closing price before Pfizer's initial acquisition announcement [2]. - Pfizer's revised offer values Metsera at up to $70 per share, amounting to around $8.1 billion [2]. Group 2: Legal and Competitive Landscape - Pfizer has filed a second lawsuit against Novo Nordisk and Metsera, claiming that Novo's attempt to outbid Pfizer is anticompetitive [3]. - The competition highlights a changing landscape in the weight loss and diabetes drug market, with Novo Nordisk currently losing market share to Eli Lilly and facing challenges from cheaper alternatives [3][4]. Group 3: Strategic Implications - For Pfizer, acquiring Metsera could provide a crucial opportunity to enter the obesity treatment market, especially after facing difficulties in launching its own obesity products [4]. - Novo Nordisk, while a pioneer in the market, is struggling to maintain investor confidence due to its drug pipeline and increasing competition [4].

Bagsværd, Denmark, 4 November 2025 – On 30 October 2025, Novo Nordisk announced the submission of an unsolicited proposal to acquire Metsera, Inc. (Metsera)1. Today, Novo Nordisk confirms that it has submitted an updated, unsolicited proposal to acquire Metsera. The updated proposal has been declared superior by Metsera’s board of directors. The acquisition of Metsera, including its early and development-stage incretin and non-incretin analogue peptide programmes, would provide Novo Nordisk the opportunity ...

Core Insights - Novo Nordisk and Pfizer have revised their bids for Metsera, an obesity drug developer [1] Company Developments - Novo Nordisk and Pfizer are actively competing for Metsera, indicating a strategic interest in the obesity treatment market [1] Industry Trends - The revision of bids by major pharmaceutical companies highlights the growing focus on obesity drug development and the potential for significant market opportunities in this sector [1]

Core Viewpoint - Pfizer (PFE.US) reported better-than-expected Q3 2025 results and raised its full-year earnings forecast, attributing the performance to ongoing cost-cutting measures that offset sales growth slowdown, which also provided funding for its acquisition of weight-loss startup Metsera (MTSR.US) [1] Financial Performance - Q3 2025 revenue decreased by 6% year-over-year to $16.654 billion, surpassing analyst expectations of $16.5 billion; adjusted net income was $4.949 billion, down 18% year-over-year; adjusted diluted EPS was $0.87, exceeding the expected $0.64 [1][2] - For the first nine months of 2025, total revenues were $45.022 billion, a 2% decline from $45.864 billion in 2024; reported net income increased by 24% to $9.419 billion [2] Business Segment Performance - The Global Biopharmaceuticals Business (Biopharma) saw a 6% decline in Q3 revenue to $16.310 billion; Pfizer CentreOne revenue increased by 21% to $344 million, while Pfizer Ignite revenue plummeted by 99% to $25 million [3] - Key drug sales showed mixed results: Comirnaty (COVID-19 vaccine) sales fell 19% to $1.151 billion; Prevnar (pneumonia vaccine) sales decreased 3% to $1.742 billion; Vyndaqel (heart failure treatment) sales grew 10% to $1.591 billion, but fell short of the $1.68 billion forecast [4] Future Outlook - Pfizer expects full-year 2025 revenue to be between $61 billion and $64 billion, with adjusted diluted EPS projected between $3.00 and $3.15, an increase from the previous forecast of $2.90 to $3.10 [5][4] Acquisition and Legal Actions - Pfizer announced a cash acquisition of Metsera at $47.50 per share, valuing the deal at approximately $4.9 billion, with potential additional payments bringing the total to $7.3 billion if certain R&D milestones are met [6] - Novo Nordisk (NVO.US) made a competing cash offer of $56.50 per share for Metsera, prompting Pfizer to file antitrust lawsuits against both Novo Nordisk and Metsera, claiming the acquisition would harm competition in the obesity treatment market [7]